Abstract：Objective：To explore the action mechanism of Shugan Jiangzhi tablets for breast cancerrelated dyslipidemia by network pharmacology and molecular docking. Methods：Effective components and action targets of the medicines contained in Shugan Jiangzhi tablets were searched through Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP)；disease targets were screened by GeneCards and DRUGBANK databases； the“medicine- active component- target- disease” network was constructed with Cytoscape3.7.2 software； the protein- protein interaction(PPI) network of core targets was constructed by STRING platform；the enrichment analysis of Gene Ontology(GO) function and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway was performed on Metascape platform for core target proteins；AutoDock Vina software was used for molecular docking between active components and core targets. Results ： A total of 104 active components and 288 potential targets of medicines ， 6 302 targets for breast cancer and 1 852 targets for dyslipidemia were screened. The main active components of medicines were quercetin，kaempferol，luteolin，naringenin，isorhamnetin and obakunone. The main core targets were serine/threonine protein kinase 1(AKT1)， tumor necrosis factor(TNF)， V- JUN sarcoma virus 17 oncogene homolog(JUN)，signal transducer and activator of transcription 3(STAT3)，tumor protein P53(TP53)，phosphatidylinositol-3-kinase(PIK3CA) and interleukin-6(IL-6). GO enrichment analysis involved biological processes such as extracellular stimulation response，cell response to lipids and cell response to lipopolysaccharide， cell components such as membrane raft， cyst cavity and endoplasmic reticulum lumen，as well as molecular functions such as receptor activity，activity of oxidoreductase and transcription factor binding. KEGG pathway enrichment analysis mainly involved AGE- RAGE signaling pathway，HIF- 1 signaling pathway and insulin resistance，etc. Molecular docking verified the good binding activity between the active components of Shugan Jiangzhi tablets and the core targets. Conclusion： The binding of quercetin， kaempferol， luteolin and isorhamnetin with the core targets AKT1， TNF， JUN and STAT3 is possibly an important mechanism of treating breast cancer-related dyslipidemia.